The global solid tumor cancer treatment market size is calculated at USD 5.64 billion in 2025 and is forecasted to reach around USD 8.76 billion by 2034, accelerating at a CAGR of 2.88% from 2025 to 2034. The North America solid tumor cancer treatment market size surpassed USD 1.8 billion in 2024 and is expanding at a CAGR of 3.01% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Solid Tumor Cancer Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Solid Tumor Cancer Treatment Market, by Type
8.1.1. Sarcomas
8.1.1.1. Market Revenue and Forecast
8.1.2. Carcinomas
8.1.2.1. Market Revenue and Forecast
9.1. Solid Tumor Cancer Treatment Market, by Treatment
9.1.1. Chemotherapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Immunotherapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Targeted Therapy
9.1.3.1. Market Revenue and Forecast
10.1. Solid Tumor Cancer Treatment Market, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. Solid Tumor Cancer Treatment Market, by End-Users
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Research Institutes
11.1.2.1. Market Revenue and Forecast
11.1.3. Homecare
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type
12.1.2. Market Revenue and Forecast, by Treatment
12.1.3. Market Revenue and Forecast, by Route of Administration
12.1.4. Market Revenue and Forecast, by End-Users
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type
12.1.5.2. Market Revenue and Forecast, by Treatment
12.1.5.3. Market Revenue and Forecast, by Route of Administration
12.1.5.4. Market Revenue and Forecast, by End-Users
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type
12.1.6.2. Market Revenue and Forecast, by Treatment
12.1.6.3. Market Revenue and Forecast, by Route of Administration
12.1.6.4. Market Revenue and Forecast, by End-Users
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type
12.2.2. Market Revenue and Forecast, by Treatment
12.2.3. Market Revenue and Forecast, by Route of Administration
12.2.4. Market Revenue and Forecast, by End-Users
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type
12.2.5.2. Market Revenue and Forecast, by Treatment
12.2.5.3. Market Revenue and Forecast, by Route of Administration
12.2.5.4. Market Revenue and Forecast, by End-Users
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type
12.2.6.2. Market Revenue and Forecast, by Treatment
12.2.6.3. Market Revenue and Forecast, by Route of Administration
12.2.6.4. Market Revenue and Forecast, by End-Users
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type
12.2.7.2. Market Revenue and Forecast, by Treatment
12.2.7.3. Market Revenue and Forecast, by Route of Administration
12.2.7.4. Market Revenue and Forecast, by End-Users
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type
12.2.8.2. Market Revenue and Forecast, by Treatment
12.2.8.3. Market Revenue and Forecast, by Route of Administration
12.2.8.4. Market Revenue and Forecast, by End-Users
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type
12.3.2. Market Revenue and Forecast, by Treatment
12.3.3. Market Revenue and Forecast, by Route of Administration
12.3.4. Market Revenue and Forecast, by End-Users
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type
12.3.5.2. Market Revenue and Forecast, by Treatment
12.3.5.3. Market Revenue and Forecast, by Route of Administration
12.3.5.4. Market Revenue and Forecast, by End-Users
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type
12.3.6.2. Market Revenue and Forecast, by Treatment
12.3.6.3. Market Revenue and Forecast, by Route of Administration
12.3.6.4. Market Revenue and Forecast, by End-Users
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type
12.3.7.2. Market Revenue and Forecast, by Treatment
12.3.7.3. Market Revenue and Forecast, by Route of Administration
12.3.7.4. Market Revenue and Forecast, by End-Users
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type
12.3.8.2. Market Revenue and Forecast, by Treatment
12.3.8.3. Market Revenue and Forecast, by Route of Administration
12.3.8.4. Market Revenue and Forecast, by End-Users
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type
12.4.2. Market Revenue and Forecast, by Treatment
12.4.3. Market Revenue and Forecast, by Route of Administration
12.4.4. Market Revenue and Forecast, by End-Users
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type
12.4.5.2. Market Revenue and Forecast, by Treatment
12.4.5.3. Market Revenue and Forecast, by Route of Administration
12.4.5.4. Market Revenue and Forecast, by End-Users
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type
12.4.6.2. Market Revenue and Forecast, by Treatment
12.4.6.3. Market Revenue and Forecast, by Route of Administration
12.4.6.4. Market Revenue and Forecast, by End-Users
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type
12.4.7.2. Market Revenue and Forecast, by Treatment
12.4.7.3. Market Revenue and Forecast, by Route of Administration
12.4.7.4. Market Revenue and Forecast, by End-Users
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type
12.4.8.2. Market Revenue and Forecast, by Treatment
12.4.8.3. Market Revenue and Forecast, by Route of Administration
12.4.8.4. Market Revenue and Forecast, by End-Users
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type
12.5.2. Market Revenue and Forecast, by Treatment
12.5.3. Market Revenue and Forecast, by Route of Administration
12.5.4. Market Revenue and Forecast, by End-Users
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type
12.5.5.2. Market Revenue and Forecast, by Treatment
12.5.5.3. Market Revenue and Forecast, by Route of Administration
12.5.5.4. Market Revenue and Forecast, by End-Users
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type
12.5.6.2. Market Revenue and Forecast, by Treatment
12.5.6.3. Market Revenue and Forecast, by Route of Administration
12.5.6.4. Market Revenue and Forecast, by End-Users
13.1. F.Hoffman- La Roche Ltd.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Mylan N.V.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Sanofi
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Pfizer
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Merck & Co
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Allergan
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AstraZeneca
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Bayer AG
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Lupin
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample